Myovant Sciences

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Myovant Sciences is a biotech company that develops new treatments for infertility in women and prostate cancer in men. The company's product capabilities and help continue to deliver innovative therapies addressing unmet patient needs in prostate cancer and women’s health. Myovant Sciences was established in 2016 and is based in Brisbane, California.

Myovant Sciences Ltd. (NYSE: MYOV) shares more than doubled on Tuesday after the firm announced results from its late-stage prostate cancer study.

Why This Is a Huge Win Against Prostate Cancer

Shares of thinly-traded, small-cap biotech Myovant Sciences Ltd (NYSE: MYOV) are skyrocketing Tuesday, the catalyst being a positive late-stage clinical readout.

Myovant's Stock Soars After Relugolix Aces Late-Stage Study For Prostate Cancer

Myovant Sciences Ltd. shares MYOV, -1.78% soared 37% in premarket trade Tuesday, after the healthcare company said a late-stage trial of a treatment for advanced prostate cancer achieved a 97% response rate.

Myovant stock soars 17% premarket on news of positive trial of prostate cancer treatment

BRISBANE, Calif. and BASEL, Switzerland, Oct.  31, 2019  (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that it has entered into a landmark agreement with Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506), a leading Japanese pharmaceutical company, on a $350 million low-interest, five-year term loan facility and an Investor Rights Agreement. This agreement was made in conjunction with Myovant’s founding shareholder, Roivant Sciences, and Sumitomo Dainippon Pharma entering into a definitive agreement for the creation of a broad strategic alliance.  At closing, the alliance entity will assume Roivant’s ownership interest in Myovant, which is expected to represent not less than a majority of Myovant’s outstanding shares.

Myovant Sciences Enters Landmark Agreement with Sumitomo Dainippon Pharma to Secure Major Financial Backing and Safeguards for Minority Shareholders

BRISBANE, Calif. and BASEL, Switzerland, Oct.  21, 2019  (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:  MYOV ), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that it has completed patient recruitment for its SPIRIT 1 study, the second of two Phase 3 replicate studies evaluating relugolix combination therapy in women with endometriosis-associated pain.

Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 1 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis

A Majority of Women and Men Report Stigma Around Menstruation; About One in Four Women Report Heavy Menstrual Bleeding or Severe Menstrual Pain A Majority of Women and Men Report Stigma Around Menstruation; About One in Four Women Report Heavy Menstrual Bleeding or Severe Menstrual Pain

First-of-Its-Kind Nationwide Survey from Myovant Sciences and Evidation Health Captures Impact of Menstrual Stigma and Symptoms

BRISBANE, Calif., and BASEL, Switzerland, Oct.  17, 2019  (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, announced today the formation of Female Forward Together, a cross-sector coalition bringing together expertise in healthcare, research, data science, digital health, and advocacy to improve women’s health. In addition to Myovant, founding members include:

Female Forward Together, a Cross-Sector Coalition, Announced to Advance Research, Education, and Action for Women’s Health

BRISBANE, Calif., and BASEL, Switzerland, Oct.  10, 2019  (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that results from its Phase 3 LIBERTY 1 & 2 studies of relugolix combination therapy in women with heavy menstrual bleeding associated with uterine fibroids will be presented in the late-breaking oral session at the 2019 American Society for Reproductive Medicine (ASRM) Scientific Congress, which is being held October 12-16 in Philadelphia, Pennsylvania.

Myovant Sciences Announces Late-Breaking Oral Presentation of Phase 3 LIBERTY 1 & 2 Study Results at 2019 American Society for Reproductive Medicine Scientific Congress

Myovant Sciences Ltd. (MYOV) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Myovant Sciences Enters Oversold Territory

BRISBANE, Calif. and BASEL, Switzerland, Sept.  06, 2019  (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced that its founding shareholder, Roivant Sciences, and Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506) (“Sumitomo Dainippon”), a leading global Japanese pharmaceutical company, have announced their entry into a  non-binding memorandum of understanding  for the creation of a broad strategic alliance. The Sumitomo Dainippon-Roivant Alliance (“Alliance”) is expected to create a new corporate entity which will be wholly owned by Sumitomo Dainippon and will assume Roivant’s ownership interest in Myovant Sciences.  The Alliance is expected to support Myovant Sciences through commercialization and profitability.  Roivant and Sumitomo Dainippon have stated that they expect to sign the definitive agreement for the Alliance by the end of October 2019.  The transaction will be subject to customary closing conditions and any required governmental approvals.

Myovant Sciences’ Founding Shareholder Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create a Broad Strategic Alliance

BRISBANE, Calif. and BASEL, Switzerland, Aug.  27, 2019  (GLOBE NEWSWIRE) -- A correction has been issued for the release disseminated today at 8:30 AM ET. The date for Lynn Seely's presentation was incorrectly listed. The complete and corrected release follows:

CORRECTION: Myovant Sciences to Participate in Upcoming September Investor Conferences

BRISBANE, Calif. and BASEL, Switzerland, Aug.  27, 2019  (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s health and prostate cancer, today announced its participation in the following upcoming investor conferences:  

Myovant Sciences to Participate in Upcoming September Investor Conferences

Myovant achieved positive results from its LIBERTY 2 phase III study using its relugolix combination therapy to treat women with uterine fibroids.

Myovant's Solid Progress Towards A Few Approvals Should Not Be Ignored

Today, we take an in-depth look at U.K.-based Myovant Sciences.

Assessing An Investment In Myovant Sciences

The company announced the pricing of a public stock offering, but investors found a silver lining.

Here's Why Myovant Sciences Jumped Today

Shares of Myovant Sciences  rose 1.6% in premarket trade Tuesday after the company announced a late-stage study of a uterine fibroid treatment met its primary endpoint and several secondary endpoints.

News for Myovant Sciences Stock (MYOV)